Comparative efficacy and safety of tenecteplase and alteplase in acute ischemic stroke: A pairwise and network meta-analysis of randomized controlled trials.

Autor: Rehman AU; Department of Neurology, King Edward Medical University, Lahore, Pakistan., Mohsin A; Department of Neurology, King Edward Medical University, Lahore, Pakistan., Cheema HA; Department of Neurology, King Edward Medical University, Lahore, Pakistan. Electronic address: huzaifaahmadcheema@gmail.com., Zahid A; Department of Neurology, King Edward Medical University, Lahore, Pakistan., Ebaad Ur Rehman M; Department of Neurology, Allama Iqbal Medical College, Lahore, Pakistan., Ameer MZ; Department of Neurology, King Edward Medical University, Lahore, Pakistan., Ayyan M; Department of Neurology, King Edward Medical University, Lahore, Pakistan., Ehsan M; Department of Neurology, King Edward Medical University, Lahore, Pakistan., Shahid A; Department of Neurology, King Edward Medical University, Lahore, Pakistan. Electronic address: abiashahid126@gmail.com., Aemaz Ur Rehman M; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Shah J; New York State Department of Health, Albany, NY, USA., Khawaja A; Department of Neurology, Wayne State University-Detroit Medical Center, Detroit, MI, USA.
Jazyk: angličtina
Zdroj: Journal of the neurological sciences [J Neurol Sci] 2023 Feb 15; Vol. 445, pp. 120537. Date of Electronic Publication: 2022 Dec 29.
DOI: 10.1016/j.jns.2022.120537
Abstrakt: Background: Studies on tenecteplase have been yielding mixed results for several important outcomes at different doses, thus hampering objective guideline recommendations in acute ischemic stroke management. This meta-analysis stratifies doses in order to refine our interpretation of outcomes and quantify the benefits and harms of tenecteplase at different doses.
Methods: PubMed/MEDLINE, the Cochrane Library, and reference lists of the included articles were systematically searched. Several efficacy and safety outcomes were pooled and reported as risk ratios (RRs) with 95% confidence intervals (CIs). Network meta-analysis was used to find the optimal dose of tenecteplase. Meta-regression was run to investigate the impact of baseline NIHSS scores on functional outcomes and mortality.
Results: Ten randomized controlled trials with a total of 4140 patients were included. 2166 (52.32%) patients were enrolled in the tenecteplase group and 1974 (47.68%) in the alteplase group. Tenecteplase at 0.25 mg/kg dose demonstrated significant improvement in excellent functional outcome at 3 months (RR 1.14, 95% CI 1.04-1.26), and early neurological improvement (RR 1.53, 95% CI 1.03-2.26). There was no statistically significant difference between tenecteplase and alteplase in terms of good functional outcome, intracerebral hemorrhage (ICH), symptomatic intracerebral hemorrhage (sICH), and 90-day mortality at any dose. Meta-regression demonstrated superior tenecteplase efficacy with increasing stroke severity, however, the results were statistically nonsignificant.
Conclusions: Tenecteplase at 0.25 mg/kg dose is more efficacious and at least as safe as alteplase for stroke thrombolysis. Newer analyses need to focus on direct comparison of tenecteplase doses and whether tenecteplase is efficacious at longer needle times.
Competing Interests: Declaration of Competing Interest The authors report no relationships that could be construed as a conflict of interest.
(Copyright © 2022 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: